Catalyst Event

Biogen Inc (BIIB) · Other

From Akros U.S. Large Cap 500 Protective Allocation Monthly Index (A500PAM)

6/4/2026, 12:00:00 AM

OtherSentiment: Positive

Biogen's next-generation spinal muscular atrophy (SMA) therapy, salanersen, received Breakthrough Therapy Designation from the U.S. FDA on 2026-06-04; a medium impact is estimated due to accelerated market entry, expected.

Korean Translation

바이오젠의 차세대 척수성 근위축증(SMA) 치료제 살라너센(salanersen)이 2026년 6월 4일 미국 FDA로부터 획기적 치료제(Breakthrough Therapy Designation)로 지정받았으며, 개발 가속화에 따른 약 5% 이상의 주가 영향이 예상됨.

Related Recent Events

View Full Timeline